We are live on ! Find out more

Regeneron Pharmaceuticals

REGN

Market cap $82.6B

801.82 USD

-3.20

0.4%

At close Updated Oct 26, 3:26 PM EDT

1 day

-0.4%

5 days

1%

1 month

6.59%

3 months

20.18%

6 months

7.71%

Year to date

3.29%

1 year

36.99%

5 years

35.41%

10 years

120.84%

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Employees: 15,410

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 17.1%

Neutral 82.6%

Negative 0.4%

Zacks Investment Research

Here's Why Regeneron (REGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Regeneron (REGN) is a Strong Value Stock

24/7 Wall Street

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings

Regeneron extends US agreement for additional supply of Ebola treatment

Regeneron said on Monday it extended its agreement with a US health authority to provide additional supply of its Ebola ‌treatment, amid a growing outbreak in Africa.

Regeneron extends US agreement for additional supply of Ebola treatment

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Zacks Investment Research

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regeneron: Is The Market Undervaluing Its Growth Potential

At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.

Regeneron: Is The Market Undervaluing Its Growth Potential

The Motley Fool

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

The Motley Fool

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

See News Rankings

Price charts implemented using Lightweight Charts™